Insmed names Will Lewis president and CEO

Tuesday, September 11, 2012 11:19 AM

Monmouth Junction, N.J.-based Insmed, a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, has appointed Will Lewis president and CEO, effective immediately.

Lewis also has been appointed to the company's board of directors. He succeeds Tim Whitten, who has resigned as president and CEO. In addition, Donald J. Hayden, Jr., who was appointed executive chairman in May, will return to his role as chairman, effective immediately.

Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries, both in the U.S. and internationally. He was a co-founder, president and chief financial officer of Aegerion Pharmaceuticals, where he played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications, enabling Aegerion to go public in one of the top IPOs of 2010. Prior to Aegerion, Lewis spent more than a decade in investment banking at JP Morgan, Robertson Stephens and Wells Fargo, involved in domestic and international capital raising and advisory work valued at more than $20 billion. He began his career as an operations officer with the Central Intelligence Agency.

"Will has worked closely with the Insmed board and management team as an advisor to the company during the past several months,” said Hayden. “I am confident he will successfully lead Insmed in its efforts to fully realize the potential our lead compound, ARIKACE, holds for patients suffering from serious orphan diseases of the lung.” 

"Insmed is approaching an important inflection point as it transitions from late-stage development of ARIKACE through to registration and commercialization," said Lewis. "Our late-stage clinical trials, including our pivotal phase III trial in CF patients, are enrolling patients quickly, and we believe this speaks to the need for and interest in ARIKACE. We believe this novel therapy has the potential to improve the lives of patients who battle CF-related Pseudomonas lung infections and non-TB mycobacteria lung infections, both high-growth orphan disease populations. Our focus in the near term will be to prepare the company for commercialization of ARIKACE in Europe and the U.S. as quickly as possible, for the benefit of both patients and Insmed shareholders."

 

Share:          
CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs